Could AI help diagnose schizophrenia?
Madeleine Finlay meets neuroscientist and psychiatrist Matthew Nour, whose research looks at how artificial intelligence could help doctors and scientists bring precision to diagnosis of psychiatric conditions. He describes his latest study looking at patients with schizophrenia, and explains how he thinks large language models such as ChatGPT could one day be used in the clinicContinue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - October 19, 2023 Category: Science Authors: Presented by Madeleine Finlay, produced by Joshan Chana, with sound design by Tony Onuchukwu. The executive producer is Ellie Bury Tags: Science Psychiatry Artificial intelligence (AI) Schizophrenia Mental health Neuroscience Society Technology Source Type: news
Robert Sapolsky Doesn ’t Believe in Free Will. (But Feel Free to Disagree.)
Shedding the concept “completely strikes at our sense of identity and autonomy,” the Stanford biologist and neurologist argues. It might also be liberating. (Source: NYT Health)
Source: NYT Health - October 16, 2023 Category: Consumer Health News Authors: Hope Reese Tags: Brain Biology and Biochemistry Conversation Sapolsky, Robert M your-feed-science your-feed-health Source Type: news
Scientists Investigating Alzheimer ’s Drug Faulted in Leaked Report
A professor at the City College of New York engaged in “significant research misconduct,” an expert committee concluded. A neuroscientist whose studies undergird an experimental Alzheimer’s drug was “reckless” in his failure to keep or provide original data, an offense that “amounts to significant…#citycollegeof #cassavasciences #hoauyanwang #citycollegeofnewyork #lindsayhburns #science #deedeemozeleski #citycollege #remibarbier #cassava (Source: Reuters: Health)
Source: Reuters: Health - October 15, 2023 Category: Consumer Health News Source Type: news
More than red blood cells depend on hemoglobin, surprising study of cartilage reveals
Blood is red because it’s brimming with the oxygen-toting protein hemoglobin, but scientists have long wondered whether cells outside of the bloodstream depend on this protein as well. Now, a team of researchers from China has demonstrated that cartilage-making cells called chondrocytes manufacture and use hemoglobin, perhaps to help them survive in cartilage’s oxygen-poor environment.
The results surprised bone researchers, but they give the study high marks. The authors “provide solid and convincing evidence that chondrocytes can produce hemoglobin and that it has a physiological role,” says bone developmen...
Source: ScienceNOW - October 13, 2023 Category: Science Source Type: news
Late-breaking data for Roche ’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis
New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to multiple sclerosis (MS)More than 90% relative reduction in new/enlarging T2 lesions and new T1 gadolinium-enhancing (Gd+) lesions with fenebrutinib beginning at 8 weeksThe safety profile of fenebrutinib was consistent with previous and ongoing clinical trials across more than 2,500 people to dateBasel, 13 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data from the Phase II FENopta study showing that inve...
Source: Roche Media News - October 13, 2023 Category: Pharmaceuticals Source Type: news
Late-breaking data for Roche ’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis
New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to multiple sclerosis (MS)More than 90% relative reduction in new/enlarging T2 lesions and new T1 gadolinium-enhancing (Gd+) lesions with fenebrutinib beginning at 8 weeksThe safety profile of fenebrutinib was consistent with previous and ongoing clinical trials across more than 2,500 people to dateBasel, 13 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data from the Phase II FENopta study showing that inve...
Source: Roche Investor Update - October 13, 2023 Category: Pharmaceuticals Source Type: news
Cassava shares plummet after investigation accuses researcher of misconduct
Shares of biotech company Cassava Sciences Inc. were slammed in extended trading Thursday, after the publication Science reported that an investigation accused a neuroscientist who often collaborated with the company of “long-standing and egregious misconduct” in data management and record keeping…#cassavasciencesinc #cassava #cuny #science #lindsayburns #wang (Source: Reuters: Health)
Source: Reuters: Health - October 13, 2023 Category: Consumer Health News Source Type: news
Co-developer of Cassava ’s potential Alzheimer’s drug cited for ‘egregious misconduct’
Cassava Sciences, a biotech company whose work on the experimental Alzheimer’s drug simufilam has been heavily criticized and is the subject of ongoing federal probes, has suffered another blow. A much-anticipated investigation by the City University of New York has accused neuroscientist Hoau-Yan Wang, a CUNY faculty member and longtime Cassava collaborator, of scientific misconduct involving 20 research papers. Many provided key support for simufilam’s jump from the lab into ongoing clinical trials.
The investigative committee found numerous signs that images were improperly manipulated, for example in a 2012
...
Source: ScienceNOW - October 12, 2023 Category: Science Source Type: news
New data for Roche ’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided
10-year efficacy data highlight OCREVUS ’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS)10-year safety data from over 6,000 patients continue to reinforce consistent long-term safety profile of OCREVUSMore than 3,200 women with MS treated with OCREVUS reported no increased risk in adverse pregnancy and infant outcomes with real-world analyses showing low risk of relapse during and after pregnancyOCREVUS controlled disease activity and progression over one year in Black and Hispanic / Latinx people with MSBasel, 12 October 2023 - Roch...
Source: Roche Media News - October 12, 2023 Category: Pharmaceuticals Source Type: news
New data for Roche ’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided
10-year efficacy data highlight OCREVUS ’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS)10-year safety data from over 6,000 patients continue to reinforce consistent long-term safety profile of OCREVUSMore than 3,200 women with MS treated with OCREVUS reported no increased risk in adverse pregnancy and infant outcomes with real-world analyses showing low risk of relapse during and after pregnancyOCREVUS controlled disease activity and progression over one year in Black and Hispanic / Latinx people with MSBasel, 12 October 2023 - Roch...
Source: Roche Investor Update - October 12, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeksOCREVUS subcutaneous injection was comparable to IV infusion in providing rapid and sustained depletion of B cells and near-complete suppression of MRI lesion activity in the brain over 24 weeksThe safety profile of OCREVUS subcutaneous injection was consistent with the well-established safety profile of OCREVUS IV infusionThe 10-minute subcutaneous injection has potential to improve the treatment experience and expand usage for people with multiple sclerosis (MS) in centres...
Source: Roche Media News - October 11, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeksOCREVUS subcutaneous injection was comparable to IV infusion in providing rapid and sustained depletion of B cells and near-complete suppression of MRI lesion activity in the brain over 24 weeksThe safety profile of OCREVUS subcutaneous injection was consistent with the well-established safety profile of OCREVUS IV infusionThe 10-minute subcutaneous injection has potential to improve the treatment experience and expand usage for people with multiple sclerosis (MS) in centres...
Source: Roche Investor Update - October 11, 2023 Category: Pharmaceuticals Source Type: news
Parkinson ’s disease detectable before physical symptoms show, Australian research finds
Exclusive: synthetic compound highlights neurodegeneration when injected into patients at early stages of disease, study showsFollow our Australia news live blog for latest updatesGet ourmorning and afternoon news emails,free app ordaily news podcastAustralian researchers have developed a way of highlighting changes in the brain that mark the progression of Parkinson ’s disease years before physical symptoms show.Researchers at the Florey Institute and Austin Health in Melbourne have shown it is possible to detect signs of Parkinson ’s disease, a debilitating neurodegenerative condition, by injecting patients with a sy...
Source: Guardian Unlimited Science - October 10, 2023 Category: Science Authors: Melissa Davey Medical editor Tags: Parkinson's disease Australia news Health Medical research Source Type: news
Neural control of gut repair | Science Signaling
Intestinal injury induces the outgrowth of adrenergic neurons that stimulate a proregenerative pathway. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - October 10, 2023 Category: Science Source Type: news
PET study questions equity of NFL ’s concussion settlement
PET brain scans of former NFL players with dementia due to repetitive head impacts do not show typical signs of Alzheimer’s disease, according to a study published October 5 in Alzheimer's Research and Therapy.The study has implications in how former players with dementia are treated and potentially compensated in the NFL’s ongoing controversial “concussion settlement,” noted first authors Robert Stern, PhD, and doctoral student Diana Trujillo-Rodriguez, of Boston University, and colleagues.“This class action settlement provides substantially higher monetary compensation to former players with a diagnosis of [Alz...
Source: AuntMinnie.com Headlines - October 10, 2023 Category: Radiology Authors: Will Morton Tags: Molecular Imaging Source Type: news
